Overnight Health Care: House Democrats slam pharma CEOs for price hikes driven by revenue, executive bonuses | Ex-FDA employees express worries to Congress over politicization of vaccines
Welcome to Wednesday night’s Overnight Health Care, where we’re waiting to see if there’s going to be a deal on a new COVID-19 relief package.
Top House Democrat: Parties ‘much closer’ to a COVID deal ‘than we’ve ever been’
The head of the House Democratic Caucus said Wednesday that the negotiators seeking an emergency coronavirus deal are “much closer” to a deal than they have been at any point during the long weeks of on-again-off-again talks.
Rep. Hakeem Jeffries (D-N.Y.) pointed to comments by Treasury Secretary Steven Mnuchin indicating a willingness to embrace $1.5 trillion in new stimulus spending – a number on par with the bipartisan relief package offered last week by the Problem Solvers Caucus – noting that that figure is far closer to the Democrats’ $2.2 trillion package than Republicans have previously backed.
After almost two months of stalled talks, Mnuchin and Speaker Nancy Pelosi (D-Calif.) have resumed the negotiations this week by phone. In some sign that progress is being made, Mnuchin met with Pelosi in the Speaker’s office on Wednesday afternoon.
Read more here.
House Democrats slam pharma CEOs for price hikes driven by revenue, executive bonuses
An explosive staff report from the Democrats on the House Oversight Committee found that the CEOs of Teva and Celgene raised drug prices exponentially for no reason other than to boost profits and inflate executives’ bonuses.
Oversight Democrats at a hearing on Wednesday pressed those CEOs, and put them on the defensive.
Highlights: Internal documents obtained by the committee found Celgene raised the price